Search result for 'ipca laboratories'

Ipca Laboratories announces 14% rise in Q4 net profit to Rs 68 crore, with revenue reaching Rs 2,247 crore. FY25 profit at Rs 738 crore.

Indian pharmaceutical stocks soared after the US exempted drugs from reciprocal tariffs. Gland Pharma and Aurobindo Pharma led the rally, gaining over 14% and 9% respectively.

Usha Madhukar Chandurkar, a promoter of Ipca Laboratories, sold a 1.6% stake in the pharmaceutical company for Rs 600 crore through an open market transaction. The shares were sold at an average...

Ipca Laboratories reported a 58% rise in consolidated net profit to Rs 229 crore in Q2 FY25, with revenue from operations reaching Rs 2,355 crore. Read more.

Ipca Laboratories reported an 18% rise in Q1 net profit to Rs 192 crore, driven by robust domestic sales. Revenue increased to Rs 2,093 crore, while exports declined.

Akums Drugs shares listed on BSE and NSE with a 7% premium over the issue price, drawing strong investor interest. The IPO was oversubscribed 63 times.

Akums Drugs and Pharmaceuticals' IPO received 63.56 times subscription on the final day, with strong participation from institutional investors. The IPO was a combination of a fresh issue and an...

Akums Drugs and Pharmaceuticals IPO receives 4.43 times subscription on Day 2, with strong interest from retail and institutional investors. The issue closes on Thursday.

Akums Drugs and Pharmaceuticals IPO was fully subscribed on Day 1, with retail investors showing strong interest. The issue will close on August 1. Learn more.

Akums Drugs and Pharmaceuticals has raised Rs 829 crore from anchor investors ahead of its IPO, which will open for subscription on July 30. The IPO is a combination of a fresh issue and an offer...

Akums Drugs and Pharmaceuticals' IPO to raise Rs 1,857 crore opens on July 30. The price band is set at Rs 646-679 per share. Learn more about the IPO details.

The EU court has upheld a EUR 13.96 million fine on Ipca Laboratories subsidiaries Unichem and Niche Generics for patent dispute settlement agreement with Servier group.

Ipca Laboratories reported a 67% jump in consolidated net profit to Rs 180 crore for the third quarter ended December 31, 2023. Revenue also increased significantly.